#### Remarks

The specification has been amended to correct typographical errors in paragraphs [0186], [0187] and [0188] that refer to variable "Q<sup>2</sup>" rather than variable "Q<sup>1</sup>". Applicants submit that the errors are obvious since these passages of the specification, as well as the passages preceding and subsequent to these passages, are directed solely to Q<sup>1</sup>, while other sections of the specification are directed to variable Q<sup>2</sup>, such as, for example, paragraphs [0045], [0083] and [0120].

Claim 24 has been amended to delete step (i) at the end of the claim.

Applicants submit that no prohibited new matter has been added by any of the amendments.

### 1. Information Disclosure Statement

On the PTO-1449 form that was filed with the IDS dated December 4, 2008 and that accompanied the current Office Action, the Examiner has indicated that copies of listed documents 6-10 and 16 were not provided.

After reviewing the documents submitted to the Patent Office in the IDS filed on December 4, 2008, Applicants confirm that copies of documents 6-10 and 16 were submitted and therefore should have been available for consideration and acknowledgement by the Examiner. Accordingly, Applicants respectfully request that the Examiner provide a copy of the PTO-1449 with documents 6-10 and 16 indicated as being considered.

## 2. Rejection under 35 U.S.C. 112, second paragraph

The rejection of claim 24 as allegedly indefinite is maintained by the Examiner due to recitation of the phrase "converting a quinazoline derivative of the formula I into another quinazoline derivative of the formula I".

Applicants continue to submit that a person of ordinary skill in the art would understand the meaning of the contested phrase and would have sufficient knowledge to chemically convert a compound encompassed by generic formula I into a different compound that is still encompassed by generic formula I. However, to expedite prosecution of this application, Applicants have deleted the contested phrase from claim 24, thereby effectively mooting this rejection.

# 3. Rejection under 35 U.S.C. 112, first paragraph

Claims 1-17, 19, 24 and 25 are rejected as allegedly failing to comply with the written description requirement. The Examiner specifically indicates that the definition of variable Q<sup>1</sup> as amended to (1-4C)alkyl and (1-4C)alkoxy (from (1-6C)alkyl and (1-6C)alkoxy) is not supported in the specification.

Applicants have amended paragraphs [0186], [0187] and [0188] in the specification to replace "Q<sup>2</sup>" with "Q<sup>1</sup>" and submit that this amendment merely corrects a typographical error and does not add prohibited new matter. As evidence for the error, Applicants point out that Q<sup>1</sup> is the sole focus of the passages of the specification that both precede and follow paragraphs [0186], [0187] and [0188]. A discussion of Q<sup>2</sup> appears in other sections of the specification. With the correction of the specification, Applicants submit that defining Q<sup>1</sup> as including (1-4C)alkyl and (1-4C)alkoxy is fully supported and therefore respectfully request that this rejection be withdrawn

### 4. Allowed Claims

Claim 18 is indicated as being allowed.

In view of the amendments and remarks presented in this response, Applicants submit that all of the pending claims should now be in a condition for allowance.

### 5. Conclusion

The foregoing amendments and remarks are being made to place the application in a condition for allowance. Applicants respectfully request reconsideration and the timely

Page 33

allowance of the pending claims. The Examiner is invited to telephone the undersigned to further prosecution of this application.

If there are any additional fees due in connection with the filing of this response, please charge the fees to our Deposit Account No. 50-0310. If a fee is required for an extension of time under 37 C.F.R. 1.136 not accounted for above, such an extension is requested and the fee should also be charged to our Deposit Account.

Dated: May 20, 2009

Morgan, Lewis & Bockius LLP Customer No. **09629** 1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004 Tel: 202-739-3000 Fax: 202-739-3001 Respectfully submitted

Morgan, Lewis & Bockius LLP

/Gregory T. Lowen/ Gregory T. Lowen

Registration No. 46,882 Direct: 202-739-5915